Clinical Trials Logo

Postmenopausal Symptoms clinical trials

View clinical trials related to Postmenopausal Symptoms.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06369363 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Estrogen Deficiency on Cardiovascular Risk

Start date: September 2025
Phase: Early Phase 1
Study type: Interventional

To explore how estrogen deficiency impacts the blood pressure (BP) and sympathetic nerve activity (SNA), and how it impacts the production of the key pro-inflammatory mediators such as Tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). It is hypothesized that estrogen deficiency increases BP, SNA and the pathway activities of the key pro-inflammatory mediators. Those effects are impacted through the downregulation of the estrogen receptor.

NCT ID: NCT06197568 Not yet recruiting - Clinical trials for Postmenopausal Symptoms

Open-Label Study of Vaginal AZU-101 in Postmenopausal Women

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Study Objectives: Primary ° To evaluate the safety and tolerability of multiple vaginal doses of AZU-101 at 3 dose levels in postmenopausal women Secondary - To assess systemic pharmacokinetics (PK) of AZU-101 - To assess the efficacy of multiple vaginal doses of AZU-101 at 3 dose levels in postmenopausal women

NCT ID: NCT05982470 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI

MIRACLE
Start date: August 18, 2023
Phase: Phase 2
Study type: Interventional

The objective of this clinical trial is to explore the efficacy of menopausal hormone therapy in early menopausal women with CSVD and MCI. The main questions it aims to answer are: - The efficacy of menopausal hormone mainly estrogen therapy for early menopausal women with CSVD and MCI - The role of MHT in delaying the progression of cognitive function, CSVD imaging features, and other clinical symptoms and the potential pathophysiological mechanisms. Participants will be divided randomly into two groups taking MHT drugs and placebo respectively and followed up for 12 months to collect relevant clinical data.

NCT ID: NCT05922800 Not yet recruiting - Hot Flashes Clinical Trials

Effectiveness of Electro-Press Needle and Gamma-Oryzanol for Menopause-associated Hot Flashes

Start date: June 19, 2023
Phase: N/A
Study type: Interventional

The investigators plan to conduct the randomized controlled trial to evaluate the effectiveness of electro-press needle (EPN), a novel acupuncture needle combining shallow and gentle insertion with transdermal electrical stimulation, on menopause-associated hot flash in comparison with gamma-oryzanol group among women during menopausal transition and postmenopausal periods.

NCT ID: NCT05634668 Not yet recruiting - Sleep Disturbance Clinical Trials

Sleep and Quality of Life Among Postmenopausal Women

Start date: December 1, 2022
Phase:
Study type: Observational

The purpose of this study is to assess the sleep quality and quality of life of the study population.

NCT ID: NCT05557799 Not yet recruiting - Clinical trials for Postmenopausal Symptoms

Photobiomodulation in Post Menopause Genitourinary Syndrome

Start date: October 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this project is to evaluate the clinical response of patients with symptoms of genitourinary menopause syndrome after the application of photobiomodulation in the vagina and its introit. METHOD: In this randomized, double-blind, placebo-controlled study protocol, women over 50 years of age who are in the postmenopausal period (amenorrhea for at least 12 months, with no pathology involved) with one or more symptoms of PGS will be selected. Participants included in the study will be randomly divided into two groups: group A, which will receive photobiomodulation with a vaginal diode laser and its introit and group B (placebo) with the laser device turned off. Both treatments will be maintained for 4 consecutive weeks.The treatment group (n=30) will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for the 40s in each site, once per week for 4 weeks. The Placebo Group (n=30) will be handled as treated, but with the laser turned off. Quality of life will be analyzed using the female sexual functioning index (FSFI-6), the urinary incontinence questionnaire (ICIQ-SF), the intensity of menopausal symptoms will be evaluated using a visual analogue scale (VAS), the vulvo vaginal atrophy will be measured by the Vaginal Health Index (VHI) and compared between groups. Also, the vaginal temperature will be measured using a thermal camera, as well as the pressure of the pelvic floor force (vaginal dynamometer) and a 1-hour Pad Test will be performed to quantify the urinary loss. The data will be tested for normality using the Shapiro Wilks test and, if they present a parametric distribution, they will be represented by means of their respective means and standard deviations.

NCT ID: NCT01170195 Not yet recruiting - Clinical trials for Postmenopausal Symptoms

Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms

Start date: September 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the proposed study is to test the effect of Licorice Root Extract- Licogen on postmenopausal symptoms in postmenopausal women. Specifically, the study will also test the effect of the licorice extract on vaginal dryness.